Welcome to our dedicated page for Shattuck Labs news (Ticker: STTK), a resource for investors and traders seeking the latest updates and insights on Shattuck Labs stock.
Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company that regularly issues news updates about its progress in developing therapies for autoimmune, inflammatory, and other immune-mediated diseases. The company’s announcements frequently focus on its lead program, SL-325, a potentially first-in-class Death Receptor 3 (DR3) blocking antibody designed to target the clinically validated DR3/TL1A pathway in inflammatory bowel disease (IBD) and related conditions.
News about Shattuck often covers key clinical and regulatory milestones for SL-325, including Investigational New Drug (IND) submissions, IND clearance, initiation of Phase 1 clinical trials in healthy volunteers, and dosing of the first participants. The company also reports on preclinical data for SL-325, such as high-affinity binding to DR3, potent inhibition of TL1A binding, and favorable safety and receptor occupancy findings in non-human primate studies.
Investors following STTK can also expect updates on Shattuck’s broader DR3-focused pipeline, including multiple preclinical DR3-based bispecific antibodies designed to inhibit both the DR3/TL1A axis and another biologically relevant target for IBD. Financing news is another recurring theme, with press releases detailing private placements, expected use of proceeds to advance SL-325 through Phase 1 and planned Phase 2 trials, and the company’s views on its cash runway.
Additional news items highlight Shattuck’s participation in medical and investor conferences, key opinion leader panels on DR3/TL1A biology and IBD, and changes to its Board of Directors associated with major financings. For readers tracking STTK, this page provides a centralized view of Shattuck’s clinical progress, scientific presentations, capital-raising activities, and governance developments as disclosed in its public communications.
Shattuck Labs, a clinical-stage biotechnology company (NASDAQ: STTK), will participate in the 11th Annual SVB Leerink Global Healthcare Conference from February 14-18, 2022. CEO Taylor Schreiber will present on February 18 at 10:40 a.m. EST. The company focuses on developing bi-functional fusion proteins for treating cancer and autoimmune diseases, currently conducting three Phase 1 clinical trials, including its SL-172154 and SL-279252 programs. A live webcast of the presentation will be available on their website, with a replay accessible for 90 days.
Shattuck Labs, Inc. (NASDAQ: STTK), a clinical-stage biotechnology firm, announced its participation in two virtual investor conferences this January 2022. CEO Taylor Schreiber will present at the H.C. Wainwright BioConnect 2022 Conference on January 10 at 7:00 a.m. EST and the 40th Annual J.P. Morgan Healthcare Conference on January 13 at 11:15 a.m. EST. The company is advancing bi-functional fusion proteins targeting cancer and autoimmune diseases, with three ongoing Phase 1 clinical trials. Webcasts will be available live and archived for 90 days on their website.
Shattuck Labs, a clinical-stage biotechnology company (NASDAQ: STTK), is set to present at the TIGIT Therapies Digital Summit 2021 from December 7-9. CEO Taylor Schreiber will present on December 9 at 9:30 a.m. EST, discussing TIGIT blockade in refractory tumors. Shattuck is advancing bi-functional fusion proteins targeting cancer and autoimmune diseases, with three ongoing Phase 1 trials. The presentation will be available for download on the company's website and to registered participants of the summit.
Shattuck Labs announced promising Phase 1 trial data for SL-172154 targeting ovarian cancer and SL-279252 for solid tumors at the SITC annual meeting. Both trials show favorable safety profiles and evidence of immune activation. An open IND for SL-172154 in acute myeloid leukemia was also disclosed. However, Shattuck and Takeda terminated their collaboration agreement. The company's Q3 financial results reveal a net loss of $17.4 million, up from $11.8 million year-over-year, with cash reserves sufficient to fund operations into 2024.
Shattuck Labs (NASDAQ: STTK) reports promising initial data from its Phase 1 clinical trials for two compounds, SL-172154 and SL-279252, targeting advanced cancers. SL-172154 shows favorable safety, high CD47 target occupancy, and potential for use in treating acute myeloid leukemia and myelodysplastic syndromes. SL-279252 exhibited anti-tumor activity in heavily pretreated melanoma patients, including one confirmed partial response. The data will be showcased at the Society for Immunotherapy of Cancer's annual meeting and discussed in a conference call on November 12, 2021.
Shattuck Labs, Inc. (NASDAQ: STTK), a biotechnology company, will host a live webcast on November 12, 2021, at 8:00 a.m. ET, to present clinical data from ongoing Phase 1 trials. The event features CEO Taylor Schreiber along with other executives discussing their lead bi-functional fusion proteins. Highlights include data for SL-172154 in ovarian cancer and SL-279252 in solid tumors and lymphoma. The presentation will be accessible via conference call and archived online for 90 days.
Austin-based Shattuck Labs (STTK) is a clinical-stage biotechnology company focused on bi-functional fusion proteins for treating cancer and autoimmune diseases. They have three ongoing Phase 1 clinical trials and announced participation in four upcoming virtual investor conferences this November. Key presentations include the Berenberg US CEO Conference on November 10 and the Cowen IO Next Summit on November 15, featuring CEO Taylor Schreiber. A live webcast of these events will be available on their website, with replays archived for 90 days.
Shattuck Labs (NASDAQ: STTK) has appointed Dr. Carrie Brownstein as a new Board member, succeeding Josiah Hornblower, the founder and former Chairman. Dr. Brownstein brings extensive experience from her role as Chief Medical Officer at Cellectis and past positions at major pharmaceutical companies. George Golumbeski, Ph.D., has been appointed as the new Chairman of the Board. This management change is expected to enhance Shattuck's strategic growth as it advances its clinical programs, particularly the SL-172154 candidate.
Shattuck Labs (NASDAQ: STTK) announced it will present four posters at the SITC’s 36th Annual Meeting from November 10-14, 2021. The presentations will cover key studies, including a Phase 1 trial of SL-172154 for platinum-resistant ovarian cancer and SL-279252 for advanced solid tumors. The company's proprietary Agonist Redirected Checkpoint (ARC®) platform aims to enhance cancer treatment by simultaneously blocking immune checkpoints and activating costimulatory pathways. These presentations highlight Shattuck's ongoing commitment to innovative cancer therapies.
Shattuck Labs, Inc. (NASDAQ: STTK), a clinical-stage biotech firm, announced its participation in three virtual investor conferences in September 2021. CEO Taylor Schreiber will lead discussions at the Citi 16th Annual BioPharma Virtual Conference on September 9, the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, and the Morgan Stanley 19th Annual Global Healthcare Conference on September 15. The company's innovative therapies focus on cancer and autoimmune diseases, including lead programs evaluated in Phase 1 trials.